Analysts have reduced their price target for DENTSPLY SIRONA from $20 to $18, reflecting adjustments to growth and valuation models after the company's recent quarterly results.
Analyst Commentary
Bullish Takeaways- Bullish analysts note the company's ongoing commitment to refining its operational model, which may lead to improved efficiency over time.
- There is optimism around DENTSPLY SIRONA's core dental markets, as stable demand could provide a foundation for gradual recovery in future quarters.
- Some analysts believe that recent cost management efforts may positively influence margins and profitability and provide upside potential if executed effectively.
- Bearish analysts express caution regarding the company's slower than expected top-line growth, which could weigh on valuation.
- Uncertainty around the pace of market recovery and delayed revenue inflection remain notable concerns that could impact near-term stock performance.
- Execution risk persists, particularly as management navigates ongoing business transformation and competitive pressures within the dental technology space.
- Analysts highlight questions about the visibility of sustainable earnings growth, leading to a more reserved outlook on the company’s shares.
What's in the News
- The SEC has concluded its investigation into DENTSPLY SIRONA's financial reporting without recommending any enforcement action. This marks a major positive development for the company (Regulatory Agency Inquiries).
- Dentsply Sirona and Pearl have formed a partnership to integrate AI-assisted 2D X-ray radiologic support into DS Core, enhancing diagnostic capabilities and patient engagement for dental professionals (Client Announcements).
- Following a thorough review, DENTSPLY SIRONA has decided to retain its Wellspect Healthcare business, citing greater long-term value for shareholders compared to a sale or other alternatives (Considering Multiple Strategic Alternatives).
- The company has reaffirmed its 2025 earnings guidance, projecting net sales between $3.60 billion and $3.70 billion, down 2.0% to 4.0% on a constant currency basis and in line with ongoing trade conditions (Corporate Guidance: New/Confirmed).
- No new share repurchases were made from April to June 2025, as the company has already completed the previously announced buyback program with over 113.7 million shares repurchased to date (Buyback Tranche Update).
Valuation Changes
- The Fair Value Estimate has decreased slightly, moving from $16.43 to $16.21 per share.
- The Discount Rate has edged down from 9.59% to 9.52%.
- Revenue Growth projections have fallen modestly from 2.30% to 2.11%.
- The Net Profit Margin is expected to improve slightly, increasing from 6.26% to 6.30%.
- The Future P/E Ratio has decreased marginally from 17.66x to 17.40x.
Have other thoughts on DENTSPLY SIRONA?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.